HCV recurrence and death after viral clearance in HCV-viremic donor to HCV-negative kidney recipient - a case report
Introduction: Effective direct-acting antiviral (DAA) therapies have transformed the landscape of kidney transplantation from HCV nucleic acid test positive donors to HCV-negative recipients (HCV NAT+/-). Meta-analyses show current DAA regimens achieved nearly universal viral eradication after HCV NAT+/- kidney transplantation. This case study presents an early HCV recurrence after initial viral clearance in HCV NAT+/- kidney transplant that rapidly progressed to fibrosing cholestatic hepatitis (FCH) and death.
Authors
- Daniel Katz (ORCID: https://orcid.org/0000-0002-6495-0078)
- Shihua He (ORCID: https://orcid.org/0009-0000-8656-658X)
- Tomohiro Tanaka (ORCID: https://orcid.org/0000-0001-7442-4912)
- Alan Reed (ORCID: https://orcid.org/0000-0001-8017-8148)
- Hassan A. Aziz (ORCID: https://orcid.org/0000-0003-3512-9982)
- Christie P. Thomas (ORCID: https://orcid.org/0000-0002-5989-9685)
- Sung‐Hoon Kim (ORCID: https://orcid.org/0000-0001-5215-7585)
- D R Thomsen
Institutions
- University of Iowa (US)
Publication Details
- Journal
- American Journal of Transplantation
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ajt.2024.12.180
- Citations
- 1
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 1.32